MEN1 and acute leukemia: Revumenib (commercial name Revuforj), an oral Menin inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in December 2024 for the treatment of R/R acute leukemia with KMT2A translocations in adult and pediatric patients aged one year and older [57].